Intercostal Cryoneurolysis Following Traumatic Rib Fractures
Phase: NA
Conditions: Rib Fractures
Sponsor: University of California, San Diego

Title: Intercostal Cryoneurolysis Following Traumatic Rib Fractures 
 
 
NCT: NCT03917823 
 
 
Date: February 19, 2020  
 
 

 
 
UCSD Human Research Protections Program 
New Biomedical Application 
RESEARCH PLAN 
Instructions for completing the Research Plan are available on the HRPP website. 
The headings on this set of instructions correspond to the headings of the Research Plan. 
General Instructions: Enter a response for all topic headings.  
Enter “Not Applicable” rather than leaving an item blank if the item does not apply to this project. 
Version date: Feb. 19, 2020 
1. 
PROJECT TITLE 
Intercostal Cryoneurolysis following Traumatic Rib Fractures 
 
2. 
PRINCIPAL INVESTIGATOR  
Brian M. Ilfeld, MD, MS 
 
3. 
FACILITIES 
UCSD hospitals:  Hillcrest, JMC, Thornton, and KOP 
 
4. 
ESTIMATED DURATION OF THE STUDY 
Three years (including follow-up and analysis) 
 
5. 
LAY LANGUAGE SUMMARY OR SYNOPSIS (no more than one paragraph) 
Rib fractures are one of the most common injuries in trauma patients. These fractures are associated 
with significant pain as well as decreased ability to inspire deeply or cough to clear secretions, which 
together lead to pulmonary complications and a high degree of morbidity and mortality. Peripheral 
nerve blocks as well as epidural blocks have been used with success to improve pain control in rib 
fracture patients and have been associated with decreased pulmonary complications and improved 
outcomes. However, a single-injection nerve block lasts less than 24 hours; and, even a continuous 
nerve block is generally limited to 3-4 days.  The pain from rib fractures usually persists for multiple 
weeks or months. In contrast to local anesthetic-induced nerve blocks, a prolonged block lasting a 
few weeks/months may be provided by freezing the nerve using a process called “cryoneurolysis”. 
The goal of this study is to evaluate the potential of cryoanalgesia to decrease pain and improve 
pulmonary mechanics in patients with rib fractures. 
 
6. 
SPECIFIC AIMS 
The ultimate objective of the proposed line of research is to determine if cryoanalgesia is an effective 
treatment for pain associated with rib fractures; and, if this analgesic modality improves pulmonary 
mechanics measured with incentive spirometry. 
 
Specific Aim 1:  To determine if, compared with current and customary analgesia for rib 
fracture(s), intercostal nerve cryoneurolysis improves maximum inspiratory volume. 
 
Hypothesis 1a:  The maximum inspired volume will be significantly increased on the day 
following the procedure [primary endpoint] as well as at other time points following the 
procedure [secondary end points] with intercostal cryoanalgesia as compared single-
injection local anesthetic-based intercostal nerve blocks [measured with an incentive 
spirometer]. 
 
Hypothesis 1b:  The maximum inspired volume as a percentage of the baseline will be 
significantly increased on the day following the procedure [secondary endpoint of greatest 
interest], as well as at other time points following the procedure [secondary end points] with 
intercostal cryoanalgesia as compared with single-injection local anesthetic-based intercostal 
nerve blocks [measured with an incentive spirometer]. 
 
 

 
 
Biomedical IRB Application Instructions 
Page 2 
 
Specific Aim 2:  To determine if, compared with current and customary analgesia, intercostal 
nerve cryoneurolysis decreases the pain associated with rib fracture(s). 
 
Hypothesis 2a:  The severity of rib fracture pain at rest will be significantly decreased within the 
12 months following the procedure with intercostal cryoneurolysis as compared with subjects 
receiving single-injection local anesthetic-based intercostal nerve blocks [measured using 
the Numeric Rating Scale for pain]. 
 
Hypothesis 2b:  The severity of rib fracture pain when using the spirometer or coughing will be 
significantly decreased within the 12 months following the procedure with intercostal 
cryoneurolysis as compared with subjects receiving single-injection local anesthetic-based 
intercostal nerve blocks [measured using the Numeric Rating Scale for pain]. 
 
Hypothesis 2c:  The incidence of chronic pain will be significantly decreased 6 and 12 months 
following a rib fracture with intercostal cryoeurolysis as compared with subjects receiving 
single-injection local anesthetic-based intercostal nerve blocks [measured using the Numeric 
Rating Scale for pain]. 
 
Hypothesis 2d:  The severity of chronic pain will be significantly decreased 6 and 12 months 
following a rib fracture with intercostal cryoneurolysis as compared with subjects receiving 
single-injection local anesthetic-based intercostal nerve blocks [measured using the Numeric 
Rating Scale for pain]. 
 
 
7. 
BACKGROUND AND SIGNIFICANCE 
Rib fractures represent a significant source of morbidity in trauma patients, with approximately 10% of 
trauma patients presenting with rib fractures.1 Pain from rib fractures is associated with decreased 
ability to cough and inspire deeply, predisposing patients to atelectasis and pulmonary complications. 
Neuraxial blocks, both thoracic epidurals and paravertebral blocks, have been associated not only with 
decreased pain, but also decreased pulmonary complications and overall mortality in patients with rib 
fractures.2 Furthermore, intercostal nerve blocks with local anesthetic have been shown to improve 
pain scores, peak expiratory flow rates, and arterial oxygen saturation on room air.3 However, 
intercostal nerve blocks are not without risk and incidence of pneumothorax has been reported as 1.4% 
for each individual intercostal nerve that is blocked.4 Although it is possible that the use of in-plane 
ultrasound guidance may decrease the risk of pneumothorax, this has not been evaluated. Additionally, 
intercostal blocks with bupivacaine have been reported to resolve in as little as six hours,5 likely due to 
the high vascularity and consequent uptake of local anesthetic from the intercostal space.  
 
An alternative analgesic technique is cryoneurolysis, consisting of the application of 
exceptionally low temperatures to reversibly ablate peripheral nerves, resulting in temporary pain 
relief termed “cryoanalgesia”.6 The intense cold temperature at the probe tip produces Wallerian 
degeneration—a reversible breakdown of the nerve axon—subsequently inhibiting transmission of 
afferent and efferent signals.  Because the nerve endoneurium, perineurium, and epineurium remain 

 
 
Biomedical IRB Application Instructions 
Page 3 
intact, the axon regenerates along the exoskeleton 
at a rate of approximately 1-2 mm/day.  While 
cryoneurolysis of peripheral nerves through 
surgical incisions has been commonly used to 
treat pain since 1961, the development of cryo 
probes that may be inserted percutaneously 
promise a revolution in the use of this modality.  
The combination of newly-designed narrow-gauge 
probes (upper right) and ultrasound now make 
percutaneous cryoanalgesia as simple as placing 
a peripheral nerve block:  the probe tip is inserted 
adjacent to the target nerve under ultrasound guidance, and a series of 2-minute freezing cycles are 
administered followed by probe withdrawal.  The procedure is essentially the same as placing an 
ultrasound-guided peripheral nerve block; however, instead of injecting local anesthetic, a 
gas circulates through the probe, inducing cold at the tip and freezing the target nerve.  
Nothing remains within the patient and there is no external equipment to prepare or manage.  
Importantly, cryoneurolysis and the probes are already approved by the United States Food and Drug 
Administration for the treatment of acute and chronic pain, so no additional regulatory approval is 
required for the proposed clinical trial. 
 
Theoretical benefits of cryoneurolysis include an ultra-long duration of pain control without opioid 
involvement, no catheter management/removal (reducing infection risk), the lack of an infusion pump 
and anesthetic reservoir to carry, an extraordinarily-low risk of infection (approaching zero), and no 
risk of local anesthetic toxicity, catheter dislodgement or leakage.  With a single 8-minute 
percutaneous cryoneurolysis procedure consisting of several freeze/defrost cycles, a truncation of 
sensory nerve conduction is induced for 6-8 weeks, with the complete restoration of nerve structure 
and function following remyelination.  Cryoneurolysis offers the possibility of potent, side effect-free 
analgesia outlasting the surgical pain, and obviating the need for postoperative opioids. 
 
8. 
PROGRESS REPORT 
We have performed several cases in which cryoneurolysis was performed after rib fractures 
producing significant and long-lasting pain relief. All patients experienced significant pain relief 
immediately, continuing for at least 2 weeks post-intervention. Numeric Rating Scale pain scores 
were consistently improved from before the procedure for multiple weeks. No adverse events 
associated with cryoanalgesia were reported in any of the patients. 
 
9. 
RESEARCH DESIGN AND METHODS 
 
The cryoneurolysis procedure will be compared with our current UCSD standard practice. 
 
 
Study Overview 
 
Day 0 
Baseline pain levels and spirometry 
 
Subjects randomized and cryoneurolysis/sham procedure administered 
 
Post-block pain levels and spirometry repeated 
 

 
 
Biomedical IRB Application Instructions 
Page 4 
Days 1, 2, 7 
Pain levels, opioid consumption, sleep disturbances due to pain, and 
incentive spirometry values collected [day of discharge recorded] 
 
Months 0.5, 1, 1.5 , 2 Pain levels, opioid consumption, sleep disturbances due to pain, and 
3, 6, and 12 
pain interference collected [if subject has spirometer available] 
 
 
 
Subjects will be individuals who present to one of the UCSD hospitals with rib fracture(s) and 
significant pain.  The University of Florida will be following the same protocol and the subjects from 
both institutions will be combined for the analysis.  Those who consent to participate in this study will 
have standard ultrasound-guided intercostal nerve blocks administered with ropivacaine 0.5% (with 
epinephrine), 3 mL/level of each fracture rib as well as one level above and one level below. 
 
Treatment group assignment (randomization).  Subjects will be allocated to one of two possible 
treatments stratified by treatment center and unilateral vs. bilateral fractures: 
 
 
 
1.  active cryoneurolysis (sham local anesthetic intercostal blocks) 
2.  sham cryoneurolysis (active local anesthetic intercostal blocks) 
 
Computer-generated randomization lists will be used to create sealed, opaque randomization 
envelopes with the treatment group assignment enclosed in each envelope labeled with the 
randomization number. 
 
The specific intercostal nerves targeted will depend on the injury site. The treatment sites will be 
cleansed with chlorhexidine gluconate and isopropyl alcohol.  Using the optimal ultrasound 
transducer for the specific anatomic location and subject anatomy (linear vs curvilinear array), the 
target nerves will be identified in a transverse cross-sectional (short axis) view.  The intercostal nerve 
of each fractured rib as well as the level above and below will be treated with the protocol below: 
 
Intercostal nerve block procedure:  The target nerve will be visualized with ultrasound.  Local 
anesthetic (1% lidocaine) will be used to infiltrate the skin and underlying muscle at each entry point.  
A 20 g Tuohy needle will be introduced through the skin wheel and along the anesthetized muscle 
tract.  For subjects randomized to active cryo, 3 mL of normal saline will be injected into the muscle 
superficial to the nerve; and for subjects randomized to sham cryo, 3 mL of ropivacaine 0.5% (with 
epinephrine) will be injected perineurally to provide the intercostal nerve block. 
 
Cryoneurolysis procedure:  Cryoneurolysis probes are available for a console neurolysis device 
(PainBlocker, Epimed, Farmers Branch, Texas) that either (1) pass nitrous oxide to the tip inducing 
freezing temperatures; or, (2) vent the nitrous oxide at the base of the probe so that no gas reaches 
the probe tip, resulting in no temperature change.  The latter is a sham procedure since without the 
temperature change, no ice ball forms and therefore the target nerve is not affected.  An 
angiocatheter/introducer will be inserted beneath the ultrasound transducer and directed until the 
probe tip is immediately adjacent to the target nerve.  The angiocatheter needle will be removed, 
leaving the angiocatheter through which the appropriate Epimed probe will be inserted until it is 
adjacent to the target nerve.  The cryoneurolysis device will be triggered using 2 cycles of 2-minute 
gas activation (active or sham) separated by 1-minute defrost periods.  For active probes, the nitrous 
oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.  
For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a 
lack of perineural temperature change. 
 

 
 
Biomedical IRB Application Instructions 
Page 5 
The process will be repeated with the same treatment probe for any additional nerves (e.g., all 
nerves will receive either active cryoneurolysis or sham/placebo, and not a mix of the two possible 
treatments). 
 
For subjects at the University of Florida, their anthropomorphic, baseline, procedure, and post-
procedure data will be recorded on the same case report form as at the University California San 
Diego and faxed to the investigators at UC San Diego following the procedure.  These faxed 
documents will remain in electronic form (eFax) on the Principal Investigator’s password-protected, 
encrypted, UCSD-owned MacBook computer.  Investigators at UC San Diego will do all of the follow-
up data collection by phone for subjects at both treatment centers. 
 
 
Outcome measurements (end points).  Anesthesia providers will perform all measures and 
assessments, which will include:   
 
1. Pain:  measured on the 11-point NRS of pain intensity 
 
2. Opioid consumption 
 
3. Pain interference:  measured using the Brief Pain Inventory (which includes the pain scores 
of #1 above) 
 
4. Sleep disturbances (#):  due to pain 
 
5. Pulmonary Mechanics:  measured by the inspired volume on a handheld incentive 
spirometer based on the American Association of Respiratory Care (AARC) clinical practice 
guideline.7  The best of three measurements will be recorded as the maximum inspired 
volume. 
 
Statistical Analysis: The primary endpoint is the maximum inspired volume measured by incentive 
spirometry the day following treatment.  There is no accepted minimal clinically-relevant change in 
incentive spirometry volume.  However, the median (IQR) of inspired volume for patients with rib 
fracture(s) is 1250 (750-1750) mL;8 and, ISV<1000 mL is associated with an increased risk of acute 
respiratory failure.8  We will therefore use the difference between 1250 and 1000 (250 mL) as the 
minimal clinically-relevant difference.  However, there is high variability in the reported increase in 
inspired volume with various regional analgesic interventions such as continuous intercostal nerve 
blocks9 and serratus plane blocks,10 and we will therefore increase our enrollment to account for an 
unpredicted increase in variability or non-normal data distribution. 
 
But, assuming a normal distribution, the interquartile range is approximately 1.35 standard deviations 
(SDs). Therefore an interquartile range of 250-50 = 200 mL (Hernandez et al. 2019) corresponds to, 
approximately, an SD of 200/1.35 = 148 mL.  Assuming this SD of 148 mL, a sample size of n=7 per 
group provides 80% power to detect a group difference of d=250 mL per group with two sided Type 1 
Error 5%.  To allow for a larger-than-anticipated SD, we will enroll 10 subjects per group with an 
evaluable primary outcome measure (n=20 for both groups combined).  Accounting for drop-outs, we 
request a maximum enrollment of 30 subjects. 
 
"Continuous data will be summarized with mean, SDs, medians, quartiles, and ranges;  and 
displayed with box-and-whisker plots by group and in aggregate.  Key baseline characteristics will be 

 
 
Biomedical IRB Application Instructions 
Page 6 
tested between groups using two-sample t-tests, and summarized with Cohen’s D, for continuous 
measures; and Fisher’s Exact test for categorical variables.  The primary outcome is maximum 
incentive spirometry volume (ISV) measured in mL on POD 1. The group difference will be tested 
using Welch’s two-sample test.  Secondary outcomes will also be tested with the two-sample t-test.  
No multiplicity adjustments will be applied for these secondary outcomes. The Wilcoxon signed-rank 
test will be used as a sensitivity analysis.  Secondary analyses will include a Mixed Model of 
Repeated Measures with fixed-effects for time, time-by-group, unilateral vs bilateral, and the number 
of fractures.  The model will treat time as a categorical variable and will assume a compound 
symmetric correlation and heterogeneous variance with respect to time. The estimated mean 
difference between groups at the final scheduled timepoint will be the parameter of interest and will 
be tested using Kenward-Roger degrees of freedom.  Out- comes only measured at baseline and a 
single follow-up timepoint will be analyses with Analysis of Covariance (ANCOVA). The dependent 
variable will be change from baseline, and covariates will include group, baseline outcome, unilateral 
vs bilateral, and the number of fractures.  Missing data is not expected due to the short follow-up in 
this study.  However, if missing data issues arise, we will use multiple imputation which is robust to 
covariate-dependent Missing at Random, and tipping point analyses under various Missing Not at 
Random assumptions." 
 
 
10. 
HUMAN SUBJECTS 
 
Inclusion criteria:  Adult patients of at least 18 years of age, (1) having a total of 1-6 rib fractures at 
least 3 cm distal to the costo-transverse joint sustained within the previous 3 days (bilateral fractures 
are acceptable, but the total of the two sides combined must not exceed 6 fractures); (2) regional 
anesthetic requested by the admitting service; and, (3) accepting of a cryoneurolysis procedure. 
 
Exclusion criteria:  (1) chronic opioid use (daily use within the 2 weeks prior to surgery and duration 
of use > 4 weeks; of note, any testing for opioid use will not occur as part of the study, but as 
standard of care); (2) pregnancy; (3) incarceration; (4) inability to communicate with the investigators; 
(5) morbid obesity (body mass index > 40 kg/m2); (6) possessing any contraindication specific to 
cryoneurolysis such as a localized infection at the treatment site, cryoglobulinemia, cold urticaria and 
Reynaud’s Syndrome; (7) any patient unable to correctly perform incentive spirometry as this is the 
primary outcome measure; (8) any patient with any degree of decreased mental capacity as 
determined by the surgical service; (9) any reason an investigator believes study participation would 
not be in the best interest of the potential subject; (10) flail chest; (11) chest tube; (12) fracture of the 
1st rib on either side; or (13) any moderate or severe pain (NRS>3) unrelated to the rib fracture(s), as 
best determined by the patient and investigator. 
 
11. 
RECRUITMENT AND PROCEDURES PREPARATORY TO RESEARCH 
Study inclusion will be proposed to eligible patients at one of the UCSD Medical Center hospitals 
(listed in #3 above)—by an investigator part of the clinical treatment team involved in the patient’s 
clinical care (HIPAA requirements will be adhered to).  There is no minimum number of hours or days 
from the time of fracture until the time of study participation and no requirement for overnight 
admission.  If a patient desires study participation, written, informed consent will be obtained using an 
IRB-approved informed consent form.   
 
Selection for inclusion will not be based on sex, race, or socioeconomic status.  For women of 
childbearing age with the possibility of pregnancy, a sample of urine is always collected for a 

 
 
Biomedical IRB Application Instructions 
Page 7 
pregnancy test prior to an invasive procedure—regardless of study participation.  Pregnant patients 
will be excluded from study participation.  
 
12. 
INFORMED CONSENT 
When a prospective subject desires, they will be provided information on the study purpose and 
protocol, as well as have any questions answered.  Candidates who meet inclusion and exclusion 
criteria and desire study enrollment will be scheduled for treatment, usually the same day or the 
following day depending on staff/equipment availability, anti-coagulation status, and other factors.  
Written informed consent will be attained prior to any measurements or procedures.  This will occur in 
private patient care rooms, so that subjects may feel comfortable asking questions. 
Subjects will be provided ample privacy and time for decision making. Surrogate consent will not be 
accepted; therefore, if human subjects cannot provide consent on their own, they will not be offered 
study enrollment.  Consent by an individual’s Legally Authorized Representative is unacceptable for 
study enrollment.  Of note, minors (age < 18 years) will not be offered enrollment.  Therefore, assent 
will not be accepted during the informed consent process. 
 
13. 
ALTERNATIVES TO STUDY PARTICIPATION 
Potential study subjects may simply decline enrollment.  They will still receive our standard-of-care 
analgesics. 
 
14. 
POTENTIAL RISKS 
1. Infection.  There is the potential risk of infection since subjects will have a probe inserted through 
the skin.  Since there will be nothing left going through the skin or in the subject after the probe is 
withdrawn, the risk of infection is very small and there has never been a report of permanent 
injury due to infection following cryoneurolysis. 
2. Bleeding.  The probe does not have an open tip and is not particularly sharp, so there is a very 
low risk of having any type of bleeding as a result of treatment.  However, if it was to happen, we 
would hold pressure until the bleeding stopped. 
3. The skin where the nerve is frozen could lose or gain color if the nerve is particularly close to the 
surface.  However, this has never been reported for deeper nerves and using the probe that will 
be used for this study. 
4. Since a nerve will be frozen, there is the chance of nerve injury.  However, in multiple decades of 
using percutaneous cryoneurolysis on peripheral nerves, only a single case of “neuritis” (nerve 
irritation) has been reported in medical journals, and this resolved after a few months. 
5. There is the risk of loss of confidentiality.  The following procedures will be done to maintain 
confidentiality:  written, paper forms will be kept in a locked medical.  Computerized records 
containing personal health information will be stored on password-protected and encrypted 
computers. 
6. The intercostal nerves run on the under surface of the ribs. Inserting a cryoneurolysis probe close 
enough to freeze these nerves therefore has a risk of injuring the lining of the lung resulting in 
pneumothorax. The risk of pneumothorax during such a procedure with ultrasound guidance is 
estimated from the literature as 1 in 2,000. However, the anesthesiologists performing these 
procedures have advanced training and years of experience that should further reduce this risk. 
7. Pain.  Cryoneurolysis has been demonstrated to provide pain relief for various chronic pain 
indications; but, it has not been rigorously investigated for acute pain states such as rib fractures.  
Therefore, subjects randomized to receive cryoneurolysis of the intercostal nerve(s) might 

 
 
Biomedical IRB Application Instructions 
Page 8 
experience more pain during the first 6-8 hours after treatment than subjects receiving a local 
anesthetic-based intercostal nerve block; but, they also might experience less pain for the 
remainder of 2 months during the period of fracture healing. 
15. RISK MANAGEMENT PROCEDURES AND ADEQUACY OF RESOURCES 
During the treatment, subjects will be continuously monitored with pulse oximetry, noninvasive blood 
pressure cuffs, and EKG (standard for nerve blocks).  If one is not already present, subjects will 
receive an IV so that emergency medications could be given, if needed.  As described above, probes 
will be placed under sterile conditions as is standard-of-care for any percutaneous cryoneurolysis. 
 
Following treatment, the subjects will be contacted daily for the first 2 days, and then on days 7 and 
14,, as well as months 1, 1.5, 2, 3, 6 and 12.  Subjects will have a physicians’ pager and cellular 
phone numbers available to respond 24 hours/day and 7 days/week for at least the first week 
following treatment. 
 
The risks to confidentiality are the release of names/ telephone numbers/ demographic data (e.g. 
weight, age, height), which will be minimized by the use of password-protected computers and case 
report forms that will be stored in locked offices. 
 
Subjects will be given clear instructions to call an investigator with any questions or concerns 
regarding their study participation.  If a patient experiences an injury that is directly caused by this 
study, medical care will be provided at the medical center.  No other compensation is offered.  Any 
adverse events will be reported to the IRB using the standard adverse events reporting and upon 
continuing review (depending on severity, as defined by the IRB). 
 
16. PRIVACY AND CONFIDENTIALITY CONSIDERATIONS INCLUDING DATA ACCESS AND MANAGEMENT 
Disposition of data.  The original, hard-copy signed informed consent forms and case report forms 
will be stored within an investigator’s locked office; and they will remain with the Principal Investigator 
for at least 7 years.  Data will be entered into an Excel spreadsheet kept on a password-protected 
and encrypted computer and retained by the Principal Investigator for at least 7 years. 
 
17. POTENTIAL BENEFITS 
For subjects randomized to receive a sham cryo treatment:  There will be no difference between 
being in this study and deciding against participation.  Therefore, there is no potential for direct 
benefits from this sham cryo “treatment”. 
 
For subjects randomized to receive active cryoneurolysis:  It is our hope that patients have a 
decrease in their acute and chronic rib fracture pain (which might permit a decreased opioid 
consumption and opioid-related nausea/vomiting) and improved pulmonary mechanics measured by 
incentive spirometry. 
 
Possible benefits to others:  Future patients may benefit if it is determined that cryoneurolysis 
decreases pain and improves pulmonary function in patients with rib fractures.  In addition, with the 
opioid epidemic, any decrease in opioid requirements would be a welcome development. 
 
18. RISK/BENEFIT RATIO 

 
 
Biomedical IRB Application Instructions 
Page 9 
Pain associated with rib fractures is often severe and debilitating. This pain makes it difficult for these 
patients to breathe deeply and cough to clear pulmonary secretions, which contributes to a high degree 
of morbidity and mortality in these patients.  Since cryoneurolysis has a very low incidence of 
complications, and there have no previous cases of permanent negative sequelae reported in the 
literature, we believe the potential risks to be minimal compared to the potential benefits.  There is the 
risk of less analgesia for the first 6-8 hours for subjects receiving active cryoneurolysis vs. those 
receiving active local anesthetic-based intercostal nerve blocks, but since cryoneurolysis results in a 
sensory block of the nerve due to Wallerian degeneration, we deem this risk to be extremely small.  
 
Subjects will be given clear verbal and written instructions to call Dr. Ilfeld or Dr. Finneran in the 
Department of Anesthesia at UCSD, with any questions or concerns regarding their study participation.  
If a patient experiences an injury that is directly caused by this study, they will receive professional 
medical care at the University of California, San Diego. No other compensation is offered.  Any adverse 
events will be reported to the UCSD IRB using the standard adverse events reporting website and on 
continuing review (depending on severity, as defined by the IRB). 
 
19. EXPENSE TO PARTICIPANT 
There will be no additional costs to subjects as a result of being in this study. 
 
20. COMPENSATION FOR PARTICIPATION 
There is no compensation for participation. 
 
21. PRIVILEGES/CERTIFICATIONS/LICENSES AND RESEARCH TEAM RESPONSIBILITIES 
Principal Investigator, Brian M. Ilfeld, MD, MS, is a board-certified anesthesiologist with fellowship 
training in and 18 post-training years of experience with regional anesthesia and acute pain 
medicine.  Dr. Ilfeld holds a license to practice medicine in California.  Dr. Ilfeld has medical 
privileges at the UC Medical Centers.  Dr. Ilfeld, or another investigator, will follow all subjects 
following their treatment.  Dr. Ilfeld will be responsible for the overall management of this study, as 
well as for the well-being of study subjects. 
 
Co-investigators, John Finneran MD, Rodney Gabriel MD, MS, and Matthew Swisher, MD, are 
board-certified or -eligible anesthesiologists with experience with regional anesthesia and acute pain 
medicine.  All hold a license to practice medicine in California and medical privileges at the UC 
Medical Centers.  All will help consent subjects, perform a history and physical exam, perform the 
treatment on subjects, and will follow subjects following their treatment. 
 
Jay Doucet, MD, Sara Edwards, MD, Todd Costantini, MD, and Allison Berndtson, MD are 
board-certified surgeons and hold licenses to practice medicine in California and medical privileges at 
the UC Medical Centers, and will help enroll subjects, perform the history and physical exam, and 
follow-up with subjects. 
 
Baharin Abdullah and Jeffrey Mills are research coordinators with the UCSD CTRI, with the 
required training—including up-to-date CITI training—for their positions. 
 
22. BIBLIOGRAPHY 
 
1. Ziegler DW, Agarwal NN. The morbidity and mortality of rib fractures. J Trauma. 1994; 37: 975–
979. 

 
 
Biomedical IRB Application Instructions 
Page 10 
 
2. Malekpour M, Hashmi A, Dove J, Torres D, Wild J. Analgesic choice in management of rib 
fractures: Paravertebral block or epidural analgesia. Anesth Analg 2017; 124(6): 1906-1911. 
 
3. Osinowo OA, Zahrani M, Softah A. Effect of intercostal nerve block with 0.5% bupivacaine on 
peak expiratory flow rate and arterial oxygen saturation in rib fractures. J Trauma Acute Care 
2004; 56(2): 345-347. 
 
4. Shanti C, Carlin A, Tyburski J. Incidence of Pneumothorax from intercostal nerve block for 
analgesia in rib fractures. J Trauma Acute Care 2001; 51(3): 536-539. 
 
5. Pedersen VM, Schulze S, Høier-Madsen K, Halkier E. Air-flow meter assessment of the effect of 
intercostal nerve block on respiratory function in rib fractures. Acta Chir Scand 1983; 149:119-
120.  
 
6. Gabriel RA, Finneran JJ, Asokan D, Trescot AM, Sandhu NS, Ilfeld BM. Ultrasound-guided 
percutaneous cryoneurolysis for acute pain management: a case report. A A Case Per. 2017; 9: 
129-132. 
 
7. Restrepo  RD, Wettstein R, Wittnebel L, Tracy M. Incentive spirometry:  2011 (AARC Clinical 
Practice Guideline).  Respir Care 2011; 56: 1600-1604. 
 
8. Butts CA, Brady JJ, Wilhelm S, Castor L, Sherwood A, McCall A, Patch J, Jones P, Cortes V, Ong 
AW. Do simple bedside lung function tests predict morbidity after rib fractures?  Am J Surg 2017; 
213: 473-477. 
 
9. Lynch N, Salottolo K, Foster K, Orlando A, Koola C, Portillo V, Tanner A, Mains CW, Bar-Or D. 
Comparative effectiveness analysis of two regional analgesia techniques for the pain 
management of isolated multiple rib fractures.  J Pain Research 2019; 12: 1701-1708. 
 
10. Hernandez N, de Haan J, Clendeninn D, Meyer DE, Ghebremichael S, Artime C, Williams G, 
Eltzschig H, Sen S.  Impact of serratus plane block on pain scores and incentive spirometry 
volumes after chest trauma.  Local Reg Anest 2019; 12: 59-66. 
 
23. FUNDING SUPPORT FOR THIS STUDY 
None. 
 
24. BIOLOGICAL MATERIALS TRANSFER AGREEMENT 
Not applicable. 
 
 
25. INVESTIGATIONAL DRUG FACT SHEET AND IND/IDE HOLDER 
Not applicable since percutaneous cryoneurolysis and the products used for this protocol are all 
cleared by the United States Food and Drug Administration for use treating both acute and chronic 
pain.  Therefore, this is an on-label study. 
 
26. IMPACT ON STAFF 

 
 
Biomedical IRB Application Instructions 
Page 11 
Participants will be enrolled by investigators and no other staff are required for this study.  Therefore 
there will not be an impact on hospital staff. 
 
27. CONFLICT OF INTEREST 
None. 
 
28. SUPPLEMENTAL INSTRUCTIONS FOR CANCER-RELATED STUDIES 
Not applicable. 
 
29. OTHER APPROVALS/REGULATED MATERIALS 
None. 
 
30. PROCEDURES FOR SURROGATE CONSENT AND/OR DECISIONAL CAPACITY ASSESSMENT 
Not applicable: surrogate consent will not be accepted.